Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

To test or not to test? Targeted therapies in GU Cancers – leveraging new...

Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud

To test or not to test? Targeted therapies in GU Cancers – leveraging new advances in clinical care ( Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud )

Addressing new treatment opportunities in localised bladder cancer

Dr Benjamin Pradere, Prof Paolo Gontero and Dr Carmen Mir

Addressing new treatment opportunities in localised bladder cancer ( Dr Benjamin Pradere, Prof Paolo Gontero and Dr Carmen Mir )

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows...

Dr Yan Zhang - Sichuan University, Chengdu, China

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC ( Dr Yan Zhang - Sichuan University, Chengdu, China )

Using AI to identify patients at increased risk of side effects from radiation...

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

ASCO GU 2024: Current best practice for mRCC

Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu

ASCO GU 2024: Current best practice for mRCC ( Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu )

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC

Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC ( Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

More from ecancer